Who is sponsoring NCT05495711?

NCT05495711 is sponsored by Sclnow Biotechnology Co., Ltd..

What condition does NCT05495711 study?

NCT05495711 studies Infertility, Female.

Is NCT05495711 still recruiting?

NCT05495711 is currently completed. Last updated 22 May 2025.

Last reviewed 2025-05-22 · How we verify

NCT05495711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

hUC Mesenchymal Stem Cells (19#iSCLife®-UT) Therapy for Patients With Thin Endometrial Infertility

Completed Phase 1 Last updated 22 May 2025

What this trial tests

Phase 1 trial testing human umbilical cord mesenchymal stem cell complex collagen in Infertility, Female in 25 participants. Completed in 1 November 2023.

Timeline

1 August 2022

Primary endpoint
1 June 2023

1 November 2023

Quick facts

Lead sponsor	Sclnow Biotechnology Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	25
Start date	1 August 2022
Primary completion	1 June 2023
Estimated completion	1 November 2023
Sites	1 location across China

Drugs / interventions tested

human umbilical cord mesenchymal stem cell complex collagen — full drug profile →
intrauterine injection

Conditions studied

Infertility, Female — all drugs for Infertility, Female →

Sponsor

Sclnow Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 20 to 39, female only, with Infertility, Female. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the therapeutic effect and safety of human umbilical cord mesenchymal stem cells on thin endometrial infertility and to explore whether human umbilical cord mesenchymal stem cells using collagen as the carrier can promote endometrial growth, reduce the recurrence rate of intrauterine adhesion, increase the clinical pregnancy rate, improve the pregnancy outcome, and study its safety.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

hUC-MSCs loaded collagen scaffold for refractory thin endometrium caused by Asherman syndrome: a double-blind randomized controlled trial.
Hou Z, Yang T, Xu D, Fu J, et al · · 2025 · cited 6× · PMID 40371958 · DOI 10.1093/stcltm/szaf011
Stem cell treatments for female reproductive disorders: a comprehensive review.
Nair R, Agarwal P, Gadre MA, Vasanthan KS, et al · · 2025 · cited 2× · PMID 40708035 · DOI 10.1186/s13048-025-01750-y
Bridging the gap: meta-epidemiological analysis on the clinical translation of stem cell-based therapies in women's reproductive diseases.
Su H, Jian Y, Tang R, Chau H, et al · · 2026 · PMID 41940375 · DOI 10.1093/hropen/hoag024
Stem cell therapy for intrauterine adhesions: a systematic review and meta-analysis of clinical outcomes.
Yuan F, Zhang Y, Qian Y, Zhou X, et al · · 2025 · PMID 41390638 · DOI 10.1186/s12884-025-08271-y

Verify or expand the search:

Other trials of human umbilical cord mesenchymal stem cell complex collagen

Trials testing the same drug.

NCT06503471 — SCLife®-UT hUC-MSCs Advanced Therapy Medicinal Products (hUC-MSCs ATMPs) for Patients With Thin Endometrial Infertility · Phase 1 · suspended

Other recruiting trials for Infertility, Female

Currently open trials in the same condition.

NCT06771401 — Identification of Biomarkers in Cervical Mucus · NA · recruiting
NCT06984081 — CAPA In-vitro Oocyte Maturation · NA · recruiting
NCT07308561 — The Relationship Between Quality of Life, Anxiety Levels, and Attitudes Toward Artificial Intelligence Among Women Under · recruiting
NCT07175571 — SISTER: Sibling Oocyte Insemination With Frozen Sperm From Third Party Donors: Evaluation of Reproductive Techniques · NA · recruiting
NCT06193135 — Usefulness of Corifollitropin α as Alternative to Conventional Daily rFSH Protocols in Oocyte Donors Undergoing Pituitar · NA · recruiting

Other Sclnow Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT03186456 — The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cereb · Phase 1 · suspended
NCT06589271 — SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration · Phase 1 · suspended
NCT03378414 — Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia · Phase 2 · not yet recruiting
NCT06503471 — SCLife®-UT hUC-MSCs Advanced Therapy Medicinal Products (hUC-MSCs ATMPs) for Patients With Thin Endometrial Infertility · Phase 1 · suspended
NCT03184935 — Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome · Phase 1, PHASE2 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05495711 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sclnow Biotechnology Co., Ltd.
Last refreshed: 22 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05495711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing